H. Jefferson Leighton received a Ph.D. in Pharmacology from the University of Virginia.
He has over 20 years of multi-national experience in the pharmaceutical industry, including11
years at Burroughs Wellcome, where he was a Principle Scientist for the Corporation, and 6
years at Glaxo, where he was a V.P. for Research and Group Director for Cardiovascular and
Metabolic Diseases. After his tenure in big pharma, Jeff became a biotech entrepreneur, founding
Inspire Pharmaceuticals, ICAgen, AdipoGenix, BioDesign and, most recently, RxDesign
Pharmaceuticals. Jeff also serves on various biopharmaceutical boards and has made key
inventions leading to development products for Hypnion (sleep medicines), Artesian (congestive
heart failure), and Descartes (pain modulation).

Recently, Dr. Leighton founded Exodos & Associated Companies, and Milestone Pharma. Presently he operates a natural products and nutrition science based company called Stronger Faster Healthier. In addition, Dr. Leighton was a co-inventor of remifentanil (Ultiva), has conceptualized
and developed to an NDA filing five other new chemical entities, and holds many other patents.
Jeff classifies his activities as those of a seasoned Drug Hunter. He lives and works in Boston.

Joel M. Linden, Ph.D., Senior Science Advisor & Co-founder

Joel M. Linden, is the Co-Founder of Adenosine Therapeutics. He is a Professor in the
Division of Inflammation Biology at the La Jolla Institute of Allergy & Immunology and a leading expert on adenosine receptors, which are
important for regulating inflammation.

Dr. Linden received a B.S. from Brown University in Applied Mathematics and Biology
and a Ph.D. from the University of Virginia in Pharmacology.

Dr. Linden has devoted the past 25 years to the study of the pharmacology, physiology
and molecular biology of adenosine receptors and has co-authored over 120 papers and 15 book
chapters on this subject. Dr. Linden is the former Chairman of the Research Committee of the
Mid-Atlantic Affiliate of the American Heart Association, has served as a member of numerous
NIH study sections, received the inventor of the year award from the University of Virginia, and
started a successful biopharmaceutical company, Adenosine Therapeutics.

Timothy L. Macdonald, Ph.D.

Professor Timothy Macdonald is a former Chair of the Department of Chemistry at the
University of Virginia. He has delivered over 100 invited lectures at universities and scientific
conferences, has written over 130 publications, and has made contributions to over a dozen
patents. The research program on which Professor Macdonald focuses works to elucidate
biological mechanisms and to develop approaches for modulating these processes. During the
past 10 years, Professor Macdonald's research program has investigated several pathways
associated with cellular proliferation, cellular defenses and idiosyncratic drug reactions and has
developed a number of agents that target these processes.

Awards received by Professor Macdonald: the Alfred P. Sloan Award, the Eli Lilly
Young Investigator Award, the Cyanamid Award for Excellence in the Advancement of
Chemical Synthesis, and, for the work on AlGlutamine, the Henderson Inventor of the Year
Award at the University of Virginia (jointly with Dr. Richard Guerrant).

Professor Macdonald received a B. S. degree from the University of California, Los
Angeles in 1971, a Ph.D. degree in chemistry from Columbia University in 1975, and undertook
postdoctoral studies at Stanford University

Henry Skinner, Ph.D.

Dr. Skinner is the representative on the board of Novartis Bioventures, Ltd. Prior to the
Novartis Venture Funds he worked as Executive Director and Global Head Strategic Alliances,
Therapeutics and Head Strategic Alliances, Technologies at the Novartis Institutes for
Biomedical Research where he led a team responsible for identification, negotiation and
management of collaborations and licenses for Novartis? therapeutic areas as well as the
technology areas.

Prior to joining Novartis he was CEO of SelectX Pharmaceuticals and President and CEO
of NeoGenesis Pharmaceuticals, which was acquired by Schering-Plough. He was also Director
of Technology Acquisitions for Pharmacia & Upjohn and Pharmacia managing business
development and licensing for Pharmacia?s research platforms and therapeutic areas worldwide,
and Director of Business Development at Lexicon Genetics. He was a postdoctoral fellow at
Baylor College of Medicine in the department of Human and Molecular Genetics and earned his
Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois. Henry serves on
the board of AMP Therapeutics, Galera Therapeutics and works with Cylene, Merus and Forma.